Paclitaxel-eluting balloon catheter - MEDRAD

Drug Profile

Paclitaxel-eluting balloon catheter - MEDRAD

Alternative Names: Cotavance

Latest Information Update: 17 Nov 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MEDRAD
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Immunosuppressants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Peripheral arterial occlusive disorders

Most Recent Events

  • 05 Nov 2014 Efficacy data from a phase I/II trial in Peripheral arterial occlusive disorders released by Covidien
  • 04 Nov 2014 Adverse events data from a phase I/II trial in Peripheral arterial occlusive disorders released by Covidien
  • 01 May 2014 Covidien and MEDRAD complete the phase I/II DEFINITIVE AR trial in Peripheral arterial occlusive disorders in Europe (NCT01366482)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top